Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation

Lei Zhang,Ruifeng Tian,Xinxin Yao,Xiao‐Jing Zhang,Peng Zhang,Yongping Huang,Zhi‐Gang She,Hongliang Li,Yan‐Xiao Ji,Jingjing Cai
DOI: https://doi.org/10.1002/hep.31277
IF: 17.298
2020-11-20
Hepatology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background &amp; Aims</h3><p>Milk fat globule‐EGF factor 8 (MFGE8) has been shown to be a critical extracellular molecule that mediates apoptotic signaling in the pathological process of nonalcoholic fatty liver disease (NAFLD). MFGE8 is abundantly expressed in hepatocyte, but its function in the pathogenesis of NAFLD has not been characterized.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach &amp; Results</h3><p>In our current study, hepatic MFGE8 showed a protective role in the pathogenesis of NAFLD. Hepatic MFGE8 deletion largely exacerbated lipid accumulation and inflammatory responses in the liver in response to overnutrition. Mechanistically, intercellular MFGE8 was shown to directly bind to apoptosis signal‐regulating kinase 1 (ASK1) and inhibits its dimerization and phosphorylation under a normal diet. However, under metabolic challenges, decreased cytoplasmic MFGE8 facilitated the dimerization and phosphorylation of ASK1 and subsequent MAPK signaling in hepatocytes.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Hepatic MFGE8 is an endogenous inhibitor that halts the progression of hepatic steatosis and inflammation. Metabolic challenge‐induced loss of intracellular MFGE8 facilitates ASK1 dimerization and phosphorylation. Therefore, maintaining hepatic MFGE8 level may serve as an alternative strategy for the treatment of NAFLD.</p></section>
gastroenterology & hepatology
What problem does this paper attempt to address?